U. S. Food and Drug Administration has commended Novartis' meningococcal vaccine Menveo and granted priority review for its multiple sclerosis pill Gilenia.

As per the estimations of the analysts, both the products have immense potential and its yearly sales may reach $1bn mark in the next few years.

The company claims that Menveo can be given to people from different age groups.

"The approval is an important milestone for adolescent immunization in the U. S. since around 16 million adolescents between 11 and 18 are at risk. The disease which can rapidly kill or debilitate previously healthy adolescents", said Andrin Oswald, Head of Novartis' vaccines and diagnostics division.

He further said that the disease infects more than 500,000 people each year, leading to more than 50,000 deaths globally.

About Gilena, ZKB's Nawrath, "For Gilenia, we remain cautious, because it's not unusual for a drug that could offer a significantly better treatment to get the priority review status".

The analysts said that Gilenia can become the first approved oral therapy for the treatment of multiple sclerosis.